Compulsive behavior in the 5-HT2C receptor knockout mouse

Physiology and Behavior

Volumn 78, Issue 4-5, 2003, Pages 641-649

  Chou Green, Jennifer M ^a   Holscher, Todd D ^a   Dallman, Mary F ^a   Akana, Susan F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 HT2C; Behavior; Knockout; Mouse; Obsessive compulsive disorder; OCD; Serotonin

Indexed keywords

PLASTIC; SEROTONIN; SEROTONIN 2C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BEHAVIOR DISORDER; BIOLOGICAL MODEL; CLAY; COMPULSION; HABITUATION; HEAD MOVEMENT; KNOCKOUT MOUSE; MALE; MASTICATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; STRAIN DIFFERENCE; WILD TYPE;

EID: 0037680378     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-9384(03)00047-7     Document Type: Article

References (42)

1. Bebbington P.E. Epidemiology of obsessive-compulsive disorder. Br. J. Psychiatry Suppl. 28(35):1998;2-6.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders. 4th ed. 1994;American Psychiatric Press, Washington (DC).
3. Thorén P., Asberg M., Cronholm B., Jörnestedt L., Träskman L. Clomipramine treatment of obsessive-compulsive disorder: I. A controlled clinical trial. Arch. Gen. Psychiatry. 37(11):1980;1281-1285.
4. Thorén P., Asberg M., Bertilsson L., Mellstrom B., Sjoqvist F., Traskman L. Clomipramine treatment of obsessive-compulsive disorder: II. Biochemical aspects. Arch. Gen. Psychiatry. 37:1980;1289-1294.
5. Montgomery S.A., McIntyre A., Osterheider M., Sarteschi P., Zitterl W., Zohar J.et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur. Neuropsychopharmacol. 3(2):1993;143-152.
6. Chouinard G., Goodman W., Greist J., Jenike M., Rasmussen S., White K.et al. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol. Bull. 26(3):1990;279-284.
7. Goodman W.K., Price L.H., Rasmussen S.A., Delgado P.L., Heninger G.R., Charney D.S. Efficacy of fluvoxamine in obsessive-compulsive disorder. Arch. Gen. Psychiatry. 46:1989;36-44.
8. McDougle C.J., Epperson C.N., Price L.H., Gelernter J. Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive-compulsive disorder. Mol. Psychiatry. 3(3):1998;270-273.
9. Frisch A., Michaelovsky E., Rockah R., Amir I., Hermesh H., Laor N.et al. Association between obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways. Eur. Neuropsychopharmacol. 10(3):2000;205-209.
10. Hoyer D., Hannon J.P., Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71(4):2002;533-554.
11. Zohar J., Mueller D.A., Insel T.R., Zohar-Kadouch R.C., Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch. Gen. Psychiatry. 44:1987;946-951.
12. Hollander E., DeCaria C.M., Nitescu A., Gully R., Suckow R.F., Cooper T.B.et al. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch. Gen. Psychiatry. 49(1):1992;21-28.
13. Ramasubbu R., Ravindran A., Lapierre Y. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. Pharmacopsychiatry. 33(6):2000;236-238.
14. Khullar A., Chue P., Tibbo P. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J. Psychiatry Neurosci. 26(1):2001;55-59.
15. Charney D.S., Goodman W.K., Price L.H., Woods S.W., Rasmussen S.A., Heninger G.R. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch. Gen. Psychiatry. 45(2):1988;177-185.
16. Ho Pian K.L., Westenberg H.G., den Boer J.A., de Bruin W.I., van Rijk P.P. Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive-compulsive disorder and controls. Biol. Psychiatry. 44(5):1998;367-370.
17. Szechtman H., Sulis W., Eilam D. Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav. Neurosci. 112(6):1998;1475-1485.
18. 1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn. J. Pharmacol. 68(1):1995;65-70.
19. Londei T., Valentini A.M.V., Leone V.G. Investigative burying by laboratory mice may involve non-functional, compulsive, behaviour. Behav. Brain Res. 94:1998;249-254.
20. Yadin E., Friedman E., Bridger W. Spontaneous alternation behavior; an animal model for obsessive-compulsive disorder. Pharmacol. Biochem. Behav. 40:1991;311-315.
21. Campbell K.M., de Lecea L., Severynse D.M., Caron M.G., McGrath M.J., Sparber S.B.et al. OCD-like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. J. Neurosci. 19(12):1999;5044-5053.
22. Joel D., Avisar A., Doljansky J. Enhancement of excessive lever-pressing after post-training signal attenuation in rats by repeated administration of the D1 antagonist SCH 23390 or the D2 agonist quinpirole, but not the D1 agonist SKF 38393 or the D2 antagonist haloperidol. Behav. Neurosci. 115(6):2001;1291-1300.
23. Greer J.M., Capecchi M.R. Hoxb8 is required for normal grooming behavior in mice. Neuron. 33(1):2002;23-34.
24. Altemus M., Glowa J.R., Galliven E., Leong Y.M., Murphy D.L. Effects of serotonergic agents on food-restriction-induced hyperactivity. Pharmacol. Biochem. Behav. 53(1):1996;123-131.
25. Woods A., Smith C., Szewczak M., Dunn R.W., Cornfeldt M., Corbett R. Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology (Berl.). 112(2-3):1993;195-198.
26. 2C serotonin receptors. Nature. 374(6522):1995;542-546.
27. 2C receptor gene. Nat. Med. 4(10):1998;1152-1156.
28. (2C) receptor mutant mice. Psychopharmacology (Berl.). 143(3):1999;309-314.
29. Madden L.J., Seeley R.J., Woods S.C. Intraventricular neuropeptide Y decreases need-induced sodium appetite and increases pica in rats. Behav. Neurosci. 113(4):1999;826-832.
30. Mitchell D., Laycock J.D., Stephen W.F. Motion sickness-induced pica in the rat. Am. J. Clin. Nutr. 30(2):1977;147-150.
31. Rocha B.A., Goulding E.H., O'Dell L.E., Mead A.N., Coufal N.G., Parsons L.H.et al. Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice. J. Neurosci. 22(22):2002;10039-10045.
32. Lalonde R., Botez M.I. Exploration of a hole-board matrix in nervous mutant mice. Brain Res. 343(2):1985;356-359.
33. File S. Factors controlling measures of anxiety and responses to novelty in the mouse. Behav. Brain Res. 125:2001;151-157.
34. Crawley J.N. Exploratory behavior models of anxiety in mice. Neurosci. Biobehav. Rev. 9(1):1985;37-44.
35. Voits M., Fink H., Gerhardt P., Hutson J. Application of 'nose-poke habituation' validation with post-trial diazepam- and cholecystokinin-induced hypo- and hyperamnesia. J. Neurosci. Methods. 57:1995;101-105.
36. Campbell K.M., McGrath M.J., Burton F.H. Differential response of cortical-limbic neuropotentiated compulsive mice to dopamine D1 and D2 receptor antagonists. Eur. J. Pharmacol. 371(2-3):1999;103-111.
37. Breiter H.C., Rauch S.L. Functional MRI and the study of OCD: from symptom provocation to cognitive-behavioral probes of cortico-striatal systems and the amygdala. NeuroImage. 4:1996;S127-S138.
38. Saxena S., Brody A.L., Schwartz J.M., Baxter L.R. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br. J. Psychiatry Suppl. 55(35):1998;26-37.
39. 2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology. 38(8):1999;1195-1205.
40. (2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse. 36(3):2000;205-221.
41. (2C) receptor mutant mice. J. Neurosci. 20(RC71):2000;1-5.
42. 2C receptor mutant mice. Proc. Natl. Acad. Sci. U. S. A. 95(25):1998;15026-15031.